Navigation Links
Studies Show Effect of BYDUREON™ on A1C and Weight for Up to Three Years
Date:6/24/2011

atients in their efforts to achieve and sustain glycemic control.(vi,vii)

About BYETTA® (exenatide) injection

BYETTA was the first glucagon-like peptide-1 (GLP-1) receptor agonist to be approved by the FDA for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone GLP-1. GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain.

BYETTA is an injectable prescription medicine that may improve blood sugar (glucose) control in adults with type 2 diabetes mellitus, when used with a diet and exercise program. BYETTA is not insulin and should not be taken instead of insulin. BYETTA is not currently recommended to be taken with insulin. BYETTA is not for people with type 1 diabetes or people with diabetic ketoacidosis. BYETTA has not been studied in people who have pancreatitis.

BYETTA provides sustained A1C control and low incidence of hypoglycemia when used alone or in combination with metformin or a thiazolidinedione, with potential weight loss (BYETTA is not a weight-loss product). BYETTA was approved in the U.S. in April 2005 and in Europe in November 2006 and has been used by more than 1.8 million patients since its introduction. See important safety information below. Additional information about BYETTA is available at www.BYETTA.com.

Important Safety Information for BYETTA® (exenatide) injection

Based on postmarketing data BYETTA has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. Patients should be observed for signs and symptoms of pancreatitis after initiation or dose escalation of BYETTA. The risk for getting low blood sugar is higher if BYETTA is taken with another medicine that can cause low blood sugar, such as a sulfonylurea. BYETTA should not be used in people who ha
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
2. Best of ASCO Features Two Studies Led by US Oncology Research Affiliated Physicians
3. Data from Clinical Studies of bioTheranostics CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting
4. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
5. Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
6. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
7. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
8. Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
9. Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO
10. New Studies Support CardioFocus HeartLight™ Endoscopic Ablation Systems Notable Treatment Results for Paroxysmal Atrial Fibrillation
11. Esperion Announces Results From Phase 1 Study and Four Preclinical Studies for ETC-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... , June 3, 2015  Flow cytometry remains ... the globe and keeping track of wide-ranging consumer ... market. In particular, ensuring user-friendliness, fluorescence capabilities, specialized ... the most important factors influencing end-user purchase decisions ... New analysis from Frost & Sullivan, ...
(Date:6/3/2015)... MALVERN, Pa. , June 3, 2015  Essential ... today that it has been invited to speak at ... New York city on June 4th.  ... Large Bore closure system, including a review of first ... systems.     MANTA closes femoral arterial punctures ...
(Date:6/3/2015)... , June 3, 2015 aTyr Pharma, Inc. ... discovery and development of Physiocrine-based therapeutics to address rare diseases, ... Annual William Blair Growth Stock Conference to be held at ... , June 9-11, 2015. John Mendlein , ... presentation on the Company at 9:20 a.m. CT on Wednesday, ...
Breaking Medicine Technology:Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 2Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 3Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 4Essential Medical Inc. Announces Participation in 2015 Jefferies Global Healthcare Conference - NYC 2
(Date:6/3/2015)... The panel of independent experts has spent ... short-listed for the awards presented tonight at TU-Automotive Detroit ... but the best-of-the-best can now be revealed as: , ... Volvo swept rivals aside by taking the coveted Car ... from our panel of expert judges., Stand out comments ...
(Date:6/3/2015)... On Sunday, June 7, 2015, tens of thousands ... local communities to observe the 28th annual National Cancer ... abroad will hold celebrations on this day to honor ... of cancer survivorship, and to show the world that ... and inspiring.,  , National Cancer Survivors Day® is an ...
(Date:6/3/2015)... June 03, 2015 DailyEndorphin is pleased ... programming module. With this highly configurable new offering, ... report on many components of its wellness programming for ... additional charge. , With this new module, annual clients ... challenges, (2) Create participant surveys, (3) Continually report on ...
(Date:6/3/2015)... DC (PRWEB) June 03, 2015 ... podiatrist Dr. Casey Friske ( Clarksville Division ... Scholarship from the Symposium of Advanced Wound Care (SAWC) ... APMA President-Elect Dr. Dan Davis. The Conference was ... B. Gonzalez Convention Center in San Antonio, TX. ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 evigilo, a ... solutions, has showcased its new branding by launching a ... , "The new brand identity: the logo depicting a ... to green, the tagline – To Know. To Act. ... path evigilo is charting. A global, borderless approach to ...
Breaking Medicine News(10 mins):Health News:TU-Automotive Awards 2015 winners revealed 2Health News:TU-Automotive Awards 2015 winners revealed 3Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 2Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 3Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 4Health News:DailyEndorphin Launches Wellness "Events" Portal 2Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Receives Award at the Spring 2015 Symposium of Advanced Wound Care Conference 2Health News:Keep calm! evigilos' "sun" will come out tomorrow – to know, to act, in time. 2
... According to researchers at,the American Society of ... homogeneous music daily may significantly reduce high blood,pressure. ... at the ASH,s Twenty-Third,Annual Scientific Meeting and Exposition ... a PERFECT example of rhythmically homogeneous,music!, SonicMood ...
... the Association of Marketing and, Communications Professionals for Inspiring Tales ... ... Triumphs, EL SEGUNDO, Calif., June 2 DaVita ... chronic kidney,disease and failure (CKD), today announced that the company,s internal,publication, ...
... that breast-feeding equally protects all babies against disease, research ... when it comes to respiratory infections, the protective effects ... boys. , Following 119 premature babies in Buenos ... that breast-feeding not only offered more protection to girls ...
... key to identifying high-risk behaviors among adolescents. Injury ... the leading causes of adolescent morbidity and mortality; yet ... behavioral concerns. That paradox of care is the motivation ... of Pediatrics, which found adolescents who participated in computerized ...
... is emerging in the world of pediatrics. A mild degree ... causes rickets in children and can be treated with increased ... sun exposure. , A new study conducted by ... study to investigate vitamin D insufficiency in pediatric patients with ...
... 1 Aflac Incorporated,announced today that Martin A. Durant ... chief financial officer. Susan R. Blanck has been,promoted to ... are,effective June 1, 2008., Durant first joined Aflac ... He was with Aflac for 10 years, eventually serving ...
Cached Medicine News:Health News:Can SonicMood Help to Significantly Lower High Blood Pressure? The Latest Research Answers With a Resounding YES! 2Health News:DaVita Magazine Takes Home Two Prestigious Hermes Creative Awards 2Health News:More girls than boys benefit from breastfeeding, Hopkins Children's research shows 2Health News:More girls than boys benefit from breastfeeding, Hopkins Children's research shows 3Health News:Waiting room gadget may prove to be a life-saver 2Health News:First study to examine vitamin D insufficiency in pediatric patients with low bone density 2Health News:Martin Durant Promoted to Executive Vice President and Deputy CFO; Sue Blanck Promoted to First Senior Vice President of Aflac Japan 2Health News:Martin Durant Promoted to Executive Vice President and Deputy CFO; Sue Blanck Promoted to First Senior Vice President of Aflac Japan 3
4 mm blade. Flat handle....
10 mm blade, angled left. Flat handle....
Double-ended. Blades set at 45 and 90 degrees. Hexagonal handle....
5 mm curved blade. Round handle....
Medicine Products: